CASI Pharmaceuticals (CASIF) Total Current Liabilities (2021 - 2025)

CASI Pharmaceuticals has reported Total Current Liabilities for 5 years, with the latest figure at $49.7 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities rose 36.26% year-over-year to $49.7 million; the trailing twelve-month figure through Dec 2025 stood at $49.7 million (up 36.26% YoY), and the FY2025 full-year result was $49.7 million, up 36.26% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $49.7 million, up from $39.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $33.7 billion in Q1 2025, with the low at $8.5 million in Q1 2024.
• Historically, Total Current Liabilities has averaged $6.6 billion across 5 years, with a median of $39.4 million in 2025.
• Annual changes were most pronounced in 2024 — Total Current Liabilities tumbled 99.78% — and 2025, when it jumped 394480.99%.
• CASI Pharmaceuticals' Total Current Liabilities stood at $13.2 million in 2021, then rose by 28.96% to $17.0 million in 2022, then surged by 98259.31% to $16.7 billion in 2023, then plunged by 99.78% to $36.5 million in 2024, then soared by 36.26% to $49.7 million in 2025.
• The last three Total Current Liabilities figures came in at $49.7 million (Q4 2025), $39.4 million (Q3 2025), and $37.7 million (Q2 2025), per Business Quant data.